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RESEARCH ARTICLE Open Access
Barriers and facilitators to recruitment and
enrollment of HIV-infected individuals with
opioid use disorder in a clinical trial
Kim A. Hoffman1* , Robin Baker1, Lynn E. Kunkel1, Elizabeth Needham Waddell1, Paula J. Lum2,
Dennis McCarty1 and P. Todd Korthuis1,3
Abstract
Background: The CTN-0067 CHOICES trial tests implementation of extended-release naltrexone (XR-NTX) versus
treatment-as-usual (TAU) for opioid use disorders (OUD) in HIV clinics to improve HIV viral suppression. The study
team investigated recruitment strategies to elucidate the barriers and facilitators to recruitment and enrollment in
the study.
Main text: Methods: Semi-structured, in-depth, digitally recorded interviews were completed with study
recruitment-related staff and medical providers (n = 26) from six participating HIV clinics in the fall of 2018.
Interviews probed 1) factors that might prevent prospective participants from engaging in study recruitment and
enrollment procedures and 2) strategies used by study staff that encourage eligible patient participation. Interviews
were transcribed and thematically analyzed using a content analysis approach. Results: All respondents reported
that barriers to recruitment and enrollment included challenging patient social and structural factors (e.g.,
homelessness or living environments with high substance use, criminal justice involvement), difficulty locating
patients with unsuppressed HIV viral load and OUD within the HIV clinic, time-consuming study enrollment
processes, and stigma around HIV and OUD which inhibited treatment seeking. Some respondents observed that
distrust of research and researchers impeded recruitment activities in the community. A specific medication-related
barrier was patient fear of opioid abstinence required prior to XR-NTX induction. Facilitators of recruitment included
use of trusted peer outreach/recruitment workers in the community, hospitalizations that offered windows of
opportunities for screening and XR-NTX induction, providing participant transportation, and partnerships with harm
reduction organizations for referrals.
Conclusions: Though study personnel encountered barriers to recruitment in the CHOICES study, persons with
untreated HIV and OUD can be enrolled in multisite clinical trials by using enhanced recruitment strategies that
extend outside of the HIV clinic. Employing peer outreach workers and collaborating with syringe service programs
may be especially helpful in facilitating recruitment and merit inclusion in similar study protocols.
Background
Substance use disorders are common in individuals with
HIV [1–5] and untreated substance use disorders (SUD)
are associated with increased HIV risk behaviors [6–8],
decreased receipt of antiretroviral therapy (ART) ([9],
2000 [7, 10];), decreased ART adherence [7, 11–13],
decreased HIV viral suppression [14, 15], greater HIV-
related symptoms [16, 17], and higher hospitalization
rates [18, 19]. Other adverse outcomes include decreased
health-related quality of life [20], greater HIV-related
symptoms [16], higher hospitalization rates [18], and
greater HIV disease progression and death [14]. Treat-
ment of SUD can increase engagement in HIV care and
enhance health outcomes [14, 21].
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Opioid antagonist therapy for individuals with HIV and
opioid use disorder
Naltrexone (NTX), a full mu-opioid antagonist, has FDA
approval for treatment of opioid use disorder but is used
infrequently because it requires daily dosing. A system-
atic review and meta-analysis of randomized studies
found that oral naltrexone was not superior to placebo
for the treatment of OUD. An extended-release formula-
tion of naltrexone (XR-NTX) lasts 28 days and elimi-
nates the need for daily dosing. XR-NTX was associated
with improved adherence and retention in treatment for
alcohol dependence [22] but has not been well tested in
people living with HIV (PLWH). A recent study, how-
ever, found that it is more difficult to induct patients
onto XR-NTX than buprenorphine [23], likely due to
the negative-opioid urine sample required before XR-
NTX induction. A 50-patient pilot study demonstrated
the feasibility of XR-NTX for the treatment of opioid
and alcohol use disorders in HIV primary care at two
HIV clinics. Mean days of opioid use in the past 30 days
decreased in both the treatment as usual (17.3 to 4.1
days) and the XR-NTX group (20.3 to 7.7 days) and HIV
suppression improved from 67 to 80% for XR-NTX and
58 to 75% for treatment as usual [24].
CTN-0067 CHOICES study
The National Drug Abuse Treatment Clinical Trials
Network “Comparing Treatments for HIV-Infected
Opioid Users in an Integrated Care Effectiveness Study
(CHOICES) Scale-up study” (CTN-0067) is a random-
ized trial of HIV clinic-based XR-NTX versus TAU
(other medications for opioid use disorder) for treatment
of opioid use disorder that began recruiting participants
in March 2018 (ClinicalTrials.gov: NCT03275350).
Clinic staff at six HIV clinics in five states completed
training in the research study protocol. The primary out-
come is HIV viral suppression at 24 weeks. Participants
must have a moderate or severe OUD and an elevated
HIV viral RNA level of ≥200 copies/ml to be eligible.
Study staff utilized a variety of traditional methods for
study recruitment, including approaching prospective
participants during clinic visits and the use of flyers. Pre-
liminary results show that study recruitment and enroll-
ment from HIV clinics have been more challenging than
anticipated at the time the study was proposed. In recent
years, the development of potent new ART agents (i.e.,
integrase inhibitors) facilitate rapid HIV viral suppres-
sion when PLWH engage in care. As such, the study eli-
gibility criteria are being applied to a harder-to-reach
population that is either undiagnosed or not engaged in
HIV care. In response, sites expanded and experimented
with different strategies in order to facilitate recruitment,
including the use of outreach workers to engage with
people in the community and recruit potential
participants.
A qualitative investigation explored staff perspectives
on the barriers and facilitators associated with study re-
cruitment and enrollment of this hard-to-reach popula-
tion during the trial’s early implementation phase.
Interviews explored a) influences that inhibited eligible
individuals from engaging in study recruitment and en-
rollment procedures and b) strategies used to encourage
study participation.
Main text
Methods
Using an iterative group process, research questions and
an interview guide were developed with the goal of bet-
ter understanding clinic staff experiences during the
study’s early implementation stages and challenges re-
lated to recruitment. We used a multiple-case, explora-
tory methodology (Mills, 2010). Two investigators
conducted in-depth interviews via in-person and tele-
phone interviews with participating staff (n = 26) from
September to November 2018. Of the 26 research staff
interviewed, 18 were women, 15 identified as white,
non-Hispanic, and 15 had a Master’s degree or higher.
The majority were study coordinators (n = 8), study cli-
nicians (n = 7), or research assistants (n = 5). Clinical ex-
perience in the fields of either HIV or addiction
medicine ranged from 1 to 31 years, and experience with
medications for the treatment of opioid use disorder
(MOUD) ranged from 1 to 24 years (Table 1). Interviews
averaged 30 min in length. All interviewees were in-
formed about confidentiality, freedom to participate and
the right to withdraw from the study at any point. The
Advarra Institutional Review Board reviewed and ap-
proved the study [25].
Qualitative interviews were recorded and transcribed.
ATLAS.ti 8.0 qualitative software facilitated coding,
organization, and retrieval of text for analysis. Thematic
codes were developed inductively as the transcripts were
reviewed, allowing the data to dictate the analytic cat-
egories [26]. After coding each transcript using coding
categories that were mutually agreed upon by three
study team members, contents of each coding category
were reviewed to ensure agreement on the nature of
respondents’ responses to the interview questions. Three
steps were taken to increase methodological rigor: 1)
multiple investigators participated in data collection and
analysis to ensure multiple viewpoints and discussion of
perceptions of data, 2) three investigators identified
emerging codes through weekly reviews to refine the
coding scheme, ensure consensus, and establish
consistency across coders, and 3) 20% of the interviews
were double-coded for inter-coder reliability and coders
agreed on 84% of the coding. The remaining coding
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inconsistencies were resolved by group discussion and
re-coded for the final dataset.
Results
Table 2 summarizes the five challenges to participant re-
cruitment and enrollment that emerged in the qualita-
tive analysis: eligibility criteria, stigma, research related
complexities, patient preferences, and social and struc-
tural barriers. Specific barriers were identified within
each challenge and sample quotations describe the
barriers.
Eligibility criteria
Study eligibility criteria required co-occurring OUD and
HIV viremia (i.e., unsuppressed viral load); respondents
reported difficulty locating patients with unsuppressed
HIV viral load and OUD within the HIV clinic and, in
some communities illicit drugs other than opioids were
more common among HIV patients.
Suppressed HIV viral loads
The requirement for a participant to have an HIV RNA
load of more than 200 copies/mL was particularly chal-
lenging because viral suppression is increasingly easier
to achieve among PLWH who are engaged in HIV treat-
ment [27].
Our viral suppression rate for our HIV patients is
about 81, or 82 percent so, I mean, we have a high
viral suppression rate.
Few patients already receiving care at HIV clinic study
sites, therefore, were eligible to participate in the study.
In order to locate PWLH with unsuppressed viral loads,
the research team had to identify and screen individuals
less engaged with care, often through HIV testing of at-
risk individuals.
For us it's a gigantic learning curve to figure out how
to reach out into the community because we've really
depended on patients walking through our door. [For
this study,] we can't wait for patients to come in.
Table 1 Respondent Characteristics
VARIABLE PARTICIPANTS (n = 26)
Age
20–29 3
30–39 11
40–49 6
50–59 3
60–69 3
Gender
Women 19
Men 6
Transgender 1
Educationa
Some college 1
Technical/associate degree 2
Bachelor 2
Master 8
PhD 5
MD 10
Study role
Site PI 4
Study clinician 7
Study coordinator 8
Research assistant 5
Outreach worker 1
QA monitor 1
Years at clinic
1–3 8
4–6 5
7–9 2
10–12 3
13–16 5
17–19 0
20+ 3
Years experience with HIV or SUD
1–3 4
4–6 6
7–9 2
10–12 2
13–16 6
17–19 2
20+ 4
Years experience with MOUD
1–3 15
4–6 4
7–9 1
Table 1 Respondent Characteristics (Continued)
VARIABLE PARTICIPANTS (n = 26)
10–12 3
13–16 2
17–19 0
20+ 1
aNumbers will equal more than 26 as some participants reported more than
1 degree
MOUD Medications for opioid use disorder treatment (e.g. naltrexone,
buprenorphine, and methadone)
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Table 2 Barriers inhibiting study recruitment and sample quotation
Theme Specific barrier Quote Potential Actionable steps
1. Eligibility
Criteria
Suppressed HIV viral
loads
People that are showing up to an HIV clinic even
sporadically have a very high suppression rate. 85
to 90%, because the medicines have just gotten
so much easier. It really is hard to find these folks
if you are sitting in the clinic.
Consider broadening eligibility criteria to include
individuals with unsuppressed HIV or drugs of
choice in a specific community. Peer outreach
workers or partnering with other organizations
can be helpful recruitment opportunities.
Opioids not the
primary drug
There’s not as many opioid users at least here as
in other parts [of the country]. Among [our]
population, [there is] more methamphetamine use.
2. Stigma Fear of learning HIV
status
The stories of people’s fears when we talk about
their diagnosis experiences and we talk about their
reactions and disclosures and all of that it’s like
we’re back in the 80s, early 90s. Especially in
[our rural community].
Ensure that staff are well trained on the stigma
that patients feel and can respond in manner
that makes them feel comfortable in the clinic.
Fear of others
learning their HIV
status
Because if you live in a town of a couple thousand
people, it’s very ‘somebody that knows somebody
that knows somebody’ sees you walking into this
[HIV] clinic. This is why we have people driving
several hours one way to come here. It gets incredibly
difficult to even locate individuals who may be
susceptible, who may be in need of MAT
Internalized stigma
and self-shaming
It’s kind of this self-shaming thing like ‘I did it to
myself, I deserve to have [HIV].’ There’s a lot of
cultural stigma and shame surrounding HIV and
Hepatitis C.…People often report their substance
use and do not tell me that they tested positive
for Hep C or HIV.
3. Research
complexities
Lengthy procedures The [patients] are [thinking], ‘I’m sitting here for
three hours, I could be out on the street making
money to get well.’ At this point a lot of them don’t
even enjoy the high, but they have to keep using
to not get sick.
Ensure that the research procedures are as
streamlined as possible while providing
adequate time to answer all questions and
concerns.
Fear of research and
outsiders
The older generation especially the older black men.
Definitely. They are like … remember what
happened … when they gave all those black men
syphilis? How will I know you are not doing that?
4. Patient
preferences
Treatment
preference
I’ve had people who were randomized into treatment
as usual [say] ‘I was looking forward to getting the
injection’ and vice versa.
Provide all of the information to the patient
about the pros and cons of each medication.
Make sure they are comfortable with either study
condition prior to randomization so that study
resources are used for patients who are willing to
follow through for either arm.
A lot of patients still view [buprenorphine] and
methadone as opioids ... Once they understand what
[XR-NTX] is, they don’t see that as a quote dependent
drug. Some people actually preferentially desire to get
onto [XR-NTX] …
Concerns about
withdrawal
When I describe precipitated withdrawal, people say,
‘Oh, is that like what happens after I use [naloxone]?’
If they have ever done that they are petrified of using
[XR-NTX] because they never want to feel like that
again.
5. Social and
structural barriers
Housing and
transportation
[Patient] had housing issues and that seemed to take
priority before being able to stop using because she
couldn’t go to inpatient just yet because she didn’t
feel secure with her housing situation.
The extent possible, assist patients with wrap-
around services such as housing referrals or
transportation services. Understand any criminal
justice involvement and how to track them
should they become incarcerated.
Mass transit in [our community] is not great. Buses
run late, there’s lots of traffic. … you have to make
so many connections and when you combine the
amount of time and the amount [of] delays, it’s very
hard for people to make appointments on time.
Criminal justice
involvement
You could be sitting with them doing an assessment
and then the next minute they walk out of your office
and boom, they are arrested, you know, you-- it’s a
revolving door.
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People that are showing up to an HIV clinic even
sporadically have a very high suppression rate. You
know, 85, 90 percent, because the medicines have just
gotten so much easier. It really is hard to find these
folks if you are sitting in the clinic.
Opioids not primary drug in the community
Some sites found recruitment challenging because opi-
oids were not the primary drug used in the community.
One site had a database of individuals that could help
them find the target population. Because methampheta-
mine was the primary drug in the community, however,
the site struggled to find PLWH who met all the criteria
for inclusion.
There's not as many opioid users at least here as in
other parts. Among this population, [there is] more
methamphetamine use. I think while it's looked at
nationally, there are regional differences.
Opioids have been in the national spotlight, but com-
munity differences in the epidemic are easily obscured.
As the inclusion/exclusion criteria become more specific,
it is important to consider the impact of each criterion
on recruitment within a specific community.
Stigma
HIV and SUD related stigmas were potent patient bar-
riers to study recruitment. Themes emerged related to
internalized stigma and prospective study participants’
fears of learning their HIV status. Other challenges in-
cluded repercussions associated with their communities
learning of their HIV status.
Fear of learning HIV status
Respondents frequently mentioned how prospective
participants’ fears of learning their HIV status inter-
fered with study recruitment: “I think we’ve learned
through the study that there’s a huge barrier just to
get tested for HIV.” Patients conveyed outdated no-
tions of what an HIV diagnosis means despite the
great medical advancements in HIV treatment: “We’ve
had patients that upon hearing the diagnosis of HIV
think that they’re going to die the next day, that it’s a
death sentence immediately.” At a rural site, a re-
spondent explained:
The stories of people’s fears when we talk about their
diagnosis experiences and we talk about their
reactions and disclosures and all of that it’s like we’re
back in the 80s, early 90s. Especially in [our rural
community]. People feel like they have to bleach their
bodies, because they’re dirty.
One site distributed harm reduction supplies (e.g.,
sterile syringes, sharps containers for safe disposal,
wound care supplies and fentanyl test strips) to encour-
age study participation. Study staff discussed the study
with prospective participants, developed rapport with
the target population, and attempted to allay their con-
cerns about learning their HIV status.
Fear of others learning of their HIV status
Respondents reported that stigma around HIV was a
more potent barrier to recruitment than having others
learn of their SUD. Respondents reported that, coupled
with the fear of learning their own HIV status, prospect-
ive study participants were concerned about family and
community members discovering their HIV status. Be-
cause if you live in a town of a couple thousand people,
it’s very ‘somebody that knows somebody that knows
somebody’ sees you walking into this [HIV] clinic. This
is why we have people driving several hours one way to
come here. It gets incredibly difficult to even locate indi-
viduals who may be susceptible, who may be in need of
MAT (medications for addiction treatment), much less
get them in and get them initiated [into the study].”
The implications varied, with some very personal con-
sequences. One respondent explained that “It’s common
practice [in] our rural HIV positive people that, if they’ve
disclosed to their family, they must eat off of disposable
plates and silverware.” While this example is certainly
stigmatizing and uncomfortable, other repercussions can
be much more severe. A clinician reported that a patient
had disclosed that members in their community “…
might kill them if they learned they were HIV positive.”
As a result of these patient concerns, study follow up
and communication were impacted:
I can’t tell you how often in the clinic I hear someone
saying ‘Well you can’t send any mail to my house that
might come from the clinic, and you can’t send my
medicines to that pharmacy because the guy who
works at the pharmacy knows my cousin and the
whole county will be talking.’ Everybody’s up in
everybody’s business. It even affects how we
communicate results.
Because there is less bias against SUD, one solution
was to use recruitment strategies that focus on the OUD
eligibility criterion before HIV status:
It's very hard for the people in our community to
walk in our door thinking that someone is going to
find out that they have HIV. That's why when we are
recruiting people we are … using the substance use
problem as the way to get people in. We will screen
them when they are here if they have HIV.
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Internalized stigma and self-shaming
Some respondents reported that when talking with pro-
spective participants, the participant disclosed feeling
ashamed and isolated, as if “there’s no one else like me.”
These feelings of internalized stigma and shame inter-
fered with completing an accurate patient history.:
It's kind of this self-shaming thing like ‘I did it to
myself, I deserve to have this’. There's a lot of cultural
stigma and shame surrounding HIV and Hepatitis C.
I've found less reported shame surrounding substance
misuse disorders. People often report their substance
use and do not tell me that they either tested positive
for Hep C or HIV. Or if I ask the question, people
tend to shut down and that takes longer for me to get
that history than the substance use history.
Respondents sough to overcome these uncomfortable
feelings with a welcoming and safe environment.
To overcome stigma and build trust while recruiting
in the community, study sites used peer outreach
workers to extend recruitment outside of the HIV clinic
and reach people actively injecting drugs and living on
the streets. One of the more successful recruitment sites
had an experienced full-time outreach worker that built
rapport by distributing safer sex supplies in the commu-
nity: “I also pass out condoms, [and] be friendly with the
drug dealers just to let them know that I’m no threat.”
Research complexities
Study enrollment required substantial time to complete
necessary blood draws, a detailed consent form, a de-
tailed psychosocial history and confirm an opioid use
disorder diagnosis. Some respondents reported that pro-
spective study participants had a fear of research, re-
searchers, and “outsiders” in general which inhibited
willingness to participate in the study.
Lengthy enrollment procedures
Some potential participants had difficulty sitting through
all the recruitment paperwork when they became anx-
ious and fidgety due to opioid withdrawal symptoms. As
a result, the recruitment process could take several days.
Attempts to break up one comprehensive enrollment
visit into several briefer, more tolerable visits were not
helpful. This approach increased the risk that sites
would lose participants or need to begin the screening
process again if they did not return on time for subse-
quent visits.
It takes less time if we do it all at once. … [I could
say] ‘We can do this part on one day, and you can
come back a few days later and we can do this part.
Then it’s less time for each visit.’ With this
population, you can’t do that. If you say, ‘Hey come in
for this part today and then in a couple days when
you have more time you can come in and do this next
part,’ they’re just gone.
One site reported that the enrollment process was
smoother for participants who were recruited during
hospitalization. This was facilitated in part by lab tests
(i.e. HIV antibody and RNA tests) which had already
been drawn during the hospital admission. Clinics affili-
ated with hospitals or other clinics developed or utilized
internal referral systems to identify out-of-care patients
and patients that had been hospitalized:
That’s one of the better recruitment methods that we
have going for us right now is our internal referrals. If
it’s a person who has fallen out of care, they’ll send a
message that says ‘hey, so-and-so is in the hospital’.
Fear of Research and outsiders
During outreach activities, study staff encountered
skepticism of research, researchers, and more generally,
outsiders coming into their community for recruitment
activities. Within the African American community,
some prospective study participants were reluctant to
engage with study staff due to the history of unethical
research conduct in their communities [28]. A research
assistant explained:
I know the people that I talk to; they always feel like
black people are being targeted … The older
generation yeah, they all complain about research
studies. Especially the older black men. Definitely.
They are like -- I guess they don't really know their
names-- the Tuskegee study -- but they are like
remember what happened with all those black men
when they gave all those black men syphilis? How will
I know you are not doing that?”
Another respondent echoed these experiences, noting
that potential participants ask “Well what about Tuske-
gee? People are experimenting on us.” Staff worked to
overcome this barrier by slowly developing trust and
rapport and by communicating how potential subjects
will be protected.I just say ‘I appreciate you respecting
me and trusting me enough to listen and learn more
about the study to just make a better decision’ …
They are starting to be more open.
Concerns about research were not limited to African
American communities. At the rural site serving a low-
income white community, concerns about research par-
ticipation emerged:
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There’s skepticism about the university in [our]
community; it’s like a research institution so they’re
already a little bit on guard when you’re trying to do
this kind of research. It’s just huge.
Another respondent working at a site in the Southern
U.S. noted that her status as an outsider to the rural
community posed a barrier to recruitment: “And even
without the color issue and the race issue, even myself
as a Caucasian female, I’m Mid-western and I may or
may not be accepted”. Another solution for gaining en-
trée to the target population has been working with syr-
inge exchange programs to get referrals.
The needle exchange has been a god send. People
come to them to exchange needles and … they have
HIV testing. Once an HIV positive individual is
identified, they immediately contact us.
Patient preferences
During recruitment, study staff discussed with partici-
pants the importance of being open to either treatment
arm and sought individuals with “willingness and readi-
ness and commitment”. Some prospective participants
had a preference for either opioid agonist therapy (TAU)
or opioid antagonist therapy (XR-NTX).
I've had people who were randomized into TAU and
were like ‘I was looking forward to getting the
injection’ and then vice versa. We've had some TAU's
that are like ‘Okay, you know, this is an opportunity,
let me take advantage of it’ and the same goes for
[XR-NTX].
When respondents were asked how individuals formed
these opinions and preferences, a research assistant ex-
plained, “I think a lot of it is community-based know-
ledge,” and that “word of mouth can have tremendous
impact.” In one case, a patient randomized to XR-NTX
did not have a positive experience and shared this liber-
ally within her community. The research associate com-
mented that this early participant had a negative impact
on subsequent recruitment as “that word spread and
made other people leery”.
Other concerns that seemed to prevent prospective
participants from engaging in the study included fear of
needles (used for the XR-NTX injection) and negative
associations with XR-NTX because of its use within jails
and drug courts: “There’s this negative connotation be-
cause for a lot of our patients [XR-NTX] equals the
criminal justice system.”
Because naltrexone is an opioid antagonist, pain man-
agement was also a concern with XR-NTX:
I’ve had a couple of patients who were like “What if I
need a dental procedure?” or “What if I have to have
surgery and I’m on this medicine?” So that’s going
around too.
Study staff have worked to overcome these concerns by
discussing non-opioid pain management alternatives.
Substituting a “drug for a drug”
Some prospective study participants did not perceive
the use of opioid agonist therapy as being drug-free. A
research assistant explained that they often heard com-
ments such as “Oh, if I’m going to kick this, it’s going
to be on my own, and through God. It’s not going to be
that I’m addicted to another substance – to a legal her-
oin”. At a clinic with rural patients, the 12-step pro-
grams in the community were described by staff as
“very much abstinence based”, and held that agonist
therapies are “trading a drug for a drug”. In these areas,
XR-NTX had an advantage for recruiting prospective
participants.
A lot of patients still view [buprenorphine] and
methadone as opioids and depending on something.
Once they understand what [XR-NTX] is, they don't
see that as a quote dependent drug. Some people
actually preferentially desire to get onto [XR-NTX] …
and, despite all odds, manage to get on it.
Concerns about withdrawal. Participants randomized
to the XR-NTX arm must be opioid free prior to in-
duction to prevent precipitated withdrawal. Patients’
concerns about opioid withdrawal symptoms were re-
cruitment barriers: A lot of our OUD clients have an
intolerance of distress and pain and feeling uncom-
fortable. They’re just not ready to make that leap.
As part of the induction protocol, clinicians may ad-
minister a naloxone challenge to confirm that patients
are opioid-free prior to the first XR-NTX injection. Pa-
tients who had prior experiences receiving naloxone to
reverse an overdose were apprehensive about the possi-
bility of precipitated withdrawal effects:
When I describe precipitated withdrawal, people then
will say, ‘Oh, is that like what happens after I use
[naloxone]?’ If they have ever done that they are
petrified of using [XR-NTX] because they never want
to feel like that again.
A facilitating factor, conversely, for recruitment
was the familiarity of prospective participants with
buprenorphine:
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Most of the patients that we have, when they come to
us they’re super interested in [buprenorphine] because
… there is a black market and illicit street use for
[buprenorphine]. A lot of people are treating
themselves. They see their community dying from
heroin and from fentanyl overdoses and they get
scared. They buy [buprenorphine] off the street from
their friend and treat themselves … People … have
experience with buprenorphine. They know it works.
They know they feel normal on it. They know they
don’t have withdrawal if they do it correctly.
Social and structural barriers
Many prospective study participants faced challenging
social and structural barriers including homelessness or
living environments with elevated rates of substance use,
criminal justice involvement, and lack of transportation.
These factors, along with ambivalence about treatment,
could impact their willingness to engage in the study.
Housing, communication, and transportation
Homelessness, phone problems, and unreliable transpor-
tation impeded prospective participants’ ability to engage
in the study. Many potential participants did not have
phones, changed phones frequently, or “do not have
minutes on their phone” to maintain contact with re-
search staff. Communication with staff was crucial, as it
may take several days for the patients to complete the
screening process, and they must return for scheduled
appointments:
There is no routine to their life so sometimes you
know, weekends run into weekdays and they might
not really remember that they have an appointment
There's no way to contact them to remind them, you
know? Something as basic as that; they just don't have
a way to remember.
Turbulent living conditions were considered to be a
universal barrier to recruitment: “Home is not a safe
place for a lot of people and so asking someone to be
there when there's all of the same kind of stressors
and inducement is really challenging”. For some,
addressing chaotic home situations takes precedence
over treatment. [Patient] had housing issues and that
seemed to take priority before being able to stop
using because she couldn't go to inpatient just yet
because she didn't feel secure with her housing
situation.
A clinician explained that in her clinic, recruiters “might
have hooked in with somebody but then the housing
falls through and then we lose them”.
Inadequate transportation was also a common barrier.
For some, this was because of the large service area. A
respondent explained that their clinic serves more than
60 counties and “Some of the people drive over two
hours one way just to come to their clinic visits, so it
can be difficult to motivate even the ideal participant to
come to research visits.” Sites that recruited primarily
from urban settings also reported that transportation
was a barrier due to inconsistent public transit and
heavy traffic:
Mass transit in [our community] is not great. Buses
run late, there's lots of traffic. It takes a long time to
get from point A to point B because you have to
make so many connections and when you combine
the amount of time and the amount [of] delays, it's
very hard for people to make appointments on time.
Access to a clinic vehicle was helpful for addressing
the transportation barrier by picking up and dropping
off participants for their enrollment visits. However, this
was only an option for those sites that already had this
option in place. This was primarily because the site had
already addressed issues such as safety, privacy, liability,
and insurance.
We transport them ourselves in this van. I can't
imagine having to set that up at the beginning of this
trial. It's something that took a lot of time and effort
to figure out and thankfully it worked well.
Some sites also utilized rideshares such as Uber and Lyft
to address transportation barriers.
Legal system involvement
Prospective participants’ on-going participation in illicit
activities such as purchasing drugs, sex work or “hustling
for money” brought them into contact with the legal sys-
tem on a regular basis. In some cases, this contact inter-
rupted the enrollment process.
It's a revolving door with our clients. You could be
sitting with them doing an assessment and then the
next minute they walk out of your office and boom,
they are arrested, you know, you-- it's a revolving
door.
In one example, a participant had successfully com-
pleted all of the screening requirements and had been
randomized to the XR-NTX arm of the study. Nonethe-
less, induction was disrupted.
We just tried so hard to get her onto the [XR-NTX]
shot and she just wasn't ready because of a lot of
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different things going on in her life and then she was
incarcerated.
Readiness to change
Coupled with social and structural difficulties, prospect-
ive study participants also faced challenges related to
“readiness-to-change” and begin substance abuse
treatment:
A lot of people are scared to stop like-- if I'm sober, if
I don't use drugs anymore, then what? So if they can
have that support like, this is what we are going to do
like the hand-holding stuff-- we are going to do this
now.
Several respondents noted patients’ reluctance to en-
gage, even after the extensive screening process was
completed.
When they are randomized into whatever group that
they are put into, that's when they realize ‘uh oh, no, I
don't want to do this’ or ‘I'm not ready’. During the
pre-screening, screening, randomization all that sec-
tion there, they are fine, they are great initially and
then when they are faced with-- you've been put in
the [XR-NTX] section or the TAU, it's like they start
to shuffle. I guess the not readiness or the not de-
cisiveness or their willingness to change
A factor that has motivated readiness for treatment in
some patients has been the sharp increase in overdose
deaths in their communities. The adulteration of heroin
with fentanyl has had a chilling effect on those who are
seeing their friends and loved ones die.
People are dying. People who have successfully been
using and doing relatively well, not over-dosing, still
alive for thirty, forty years, now are having friends that
are dying and have overdosed. Coming and saying I'm
scared that I could die, the stuff that's out there is not
what it used to be. I got to do something about it.
Recruiters used motivational interviewing techniques
to assist patients who were feeling ready “to do some-
thing” but perhaps still ambivalent. Motivational inter-
views helped prospective patients see the costs and risks
of continued use.
The motivational interviewing is helpful in getting to
that point, in teasing out the information that we
would need in order to address any concerns the
participant might have in order to help them
recognize what their wants are.
These “wants” and goals of participants varied and in-
cluded desires to “rekindle relationships, make things
right”, re-gain custody of children, find employment and
financial stability, establish stable housing and other
factors.
Conclusion
Respondents reported barriers that hindered recruitment
and enrollment and methods to overcome these barriers
to enrollment in the CTN-0067 CHOICES clinical trial.
As these barriers came into focus, study sites found
strategies to facilitate enrollment. For example, patient
transportation barriers could be overcome by use of a
clinic vehicle. Rideshares are a viable alternative solution
but required additional funding.
Patient attitudes and preferences for a particular study
drug affected study participation. While site staff worked
to ensure that potential participants were willing to be
assigned to either XR-NTX or buprenorphine, staff also
reported that participants retained preferences despite
agreeing to be assigned to either medication. This re-
sulted in some participants being lost to follow up when
they were not randomized to the medication they pre-
ferred. Treatment preference was associated with study
drug initiation and retention in a recent comparative ef-
fectiveness trial of XR-NTX versus buprenorphine/na-
loxone in patients admitted for medically supervised
withdrawal [23].
Study sites expanded recruitment strategies to include
individuals who were new to HIV treatment and people
with opioid use disorders who were either out-of-HIV
treatment or not previously diagnosed with an HIV in-
fection. The most successful sites a) developed local
partnerships with other organizations or referral sources;
b) had strong street-level outreach activities and the use
of peer patient navigators; and c) forged systems for in-
ternal referrals when patients were hospitalized.
Several limitations of the study should be acknowledged.
The study was exploratory and assessed barriers to re-
cruitment and enrollment in a national multisite random-
ized trial of XR-NTX vs. TAU for the treatment of OUD
in persons with unsuppressed HIV disease. Thus, the find-
ings from this study may not generalize to other trials of
substance use disorder treatment or those involving
persons without HIV infection. The study focused on
provider perspectives; future studies will examine the bar-
riers and facilitators to enrollment from the patient per-
spective. The small sample size early in enrollment did
not allow for statistical tests to examine differences by
organizational or individual demographics such as recruit-
ment site or participant race. Quantitative analysis of asso-
ciations between individual demographics, organizational
characteristic and study recruitment and retention will be
assessed when enrollment targets are met.
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Persons with untreated HIV and OUD can be enrolled
in multisite clinical trials by using enhanced recruitment
strategies that extend outside of the HIV clinic. Employ-
ing peer outreach workers and collaborating with syringe
service programs may be especially helpful in facilitating
recruitment and merit inclusion in the study protocol
and its implementation. Respondents’ perspectives pro-
vide valuable information for designing, implementing,
and evaluating recruitment and enrollment strategies for
other substance use disorder treatment studies and ser-
vices for persons living with HIV. Results demonstrate
the importance of these barriers for SUD researchers
and, by extension, treatment providers.
This exploratory analysis examined barriers and facili-
tators to study recruitment and enrollment in the CTN-
0067 CHOICES clinical trial comparing the effectiveness
of XR-NTX versus TAU for HIV-infected persons with
opioid use disorder. Respondents identified a range of is-
sues that impeded patient participation in the study in-
cluding stigma, narrow eligibility criteria, lengthy
enrollment procedures, patient preferences about study
arm, and social and structural factors that increase pa-
tient complexity. Although it was not possible to alter
our eligibility criteria, future studies may want to con-
sider broadening eligibility criteria to include individuals
with unsuppressed HIV or targeting the varying drugs of
choice in a specific community. Helpful tactics study
sites were able to employ included ensuring that staff
understood the stigma that patients feel and making
them feel as comfortable as possible in the clinic. This
included trying to ensure that the research procedures
were as streamlined as possible while providing adequate
time to answer all questions and concerns. Staff also
worked diligently to provide all of the information to the
patients about the pros and cons of each medication, so
that they were willing to enroll in the study despite the
condition they were randomized to. Though study
personnel encountered barriers to recruitment in the
CHOICES study, persons with untreated HIV and OUD
can be enrolled in multisite clinical trials by using en-
hanced recruitment strategies that extend outside of the
HIV clinic. Employing peer outreach workers and collab-
orating with syringe service programs may be especially
helpful in facilitating recruitment and merit inclusion in
similar study protocols.
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